208 related articles for article (PubMed ID: 9590570)
1. Absence of detectable regression of human hypertensive left ventricular hypertrophy following drug treatment for 1 year.
Laufer E; Reid C; Qi XL; Jennings GL
Clin Exp Pharmacol Physiol; 1998; 25(3-4):208-15. PubMed ID: 9590570
[TBL] [Abstract][Full Text] [Related]
2. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Gottdiener JS; Reda DJ; Massie BM; Materson BJ; Williams DW; Anderson RJ
Circulation; 1997 Apr; 95(8):2007-14. PubMed ID: 9133508
[TBL] [Abstract][Full Text] [Related]
3. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Nyström F; Malmqvist K; Ohman KP; Kahan T
J Hypertens; 2002 Aug; 20(8):1527-33. PubMed ID: 12172314
[TBL] [Abstract][Full Text] [Related]
4. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
6. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
7. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
[TBL] [Abstract][Full Text] [Related]
8. Nitrendipine vs. captopril in essential hypertension: effects on circadian blood pressure and left ventricular hypertrophy.
Machnig T; Henneke KH; Engels G; Pongratz G; Schmalzl M; Gellert J; Bachmann K
Cardiology; 1994; 85(2):101-10. PubMed ID: 7954561
[TBL] [Abstract][Full Text] [Related]
9. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure.
Dyadyk AI; Bagriy AE; Lebed IA; Yarovaya NF; Schukina EV; Taradin GG
Nephrol Dial Transplant; 1997 May; 12(5):945-51. PubMed ID: 9175047
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Barrios V; Escobar C; Tomás JP; Calderon A; Echarri R
Clin Ther; 2008 Jan; 30(1):98-107. PubMed ID: 18343246
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study.
Verdecchia P; Schillaci G; Reboldi GP; Sacchi N; Bruni B; Benemio G; Porcellati C
Blood Press Monit; 2000 Jun; 5(3):187-93. PubMed ID: 10915233
[TBL] [Abstract][Full Text] [Related]
13. Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis.
Georgianos PI; Agarwal R
Am J Kidney Dis; 2015 Aug; 66(2):305-12. PubMed ID: 25818679
[TBL] [Abstract][Full Text] [Related]
14. Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study.
Magometschnigg D; Brandt D; Hofmann R; Sihorsch K; Stoschitzky K; Zangeneh M; Zenker G
Int J Clin Pharmacol Ther; 1997 Sep; 35(9):389-96. PubMed ID: 9314093
[TBL] [Abstract][Full Text] [Related]
15. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J
J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
[TBL] [Abstract][Full Text] [Related]
16. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
Middeke M; Richter WO; Schwandt P; Holzgreve H
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
[TBL] [Abstract][Full Text] [Related]
17. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
18. Comparison of captopril-thiazide and enalapril-thiazide combinations in the management of mild to moderate black hypertensive patients: how important is diuretic dose and duration of action of the ACE-inhibitor?
Skoularigis J; Strugo V; Zambakides C; Eintracht S; Reddy K; Tshele E; Smith D; Sareli P
Int J Clin Pharmacol Ther; 1996 Jun; 34(6):263-8. PubMed ID: 8793612
[TBL] [Abstract][Full Text] [Related]
19. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Okin PM; Hille DA; Kjeldsen SE; Lindholm LH; Edelman JM; Dahlöf B; Devereux RB
Am J Hypertens; 2010 Jul; 23(7):786-93. PubMed ID: 20395941
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
Jordan J; Engeli S; Boschmann M; Weidinger G; Luft FC; Sharma AM; Kreuzberg U
J Hypertens; 2005 Dec; 23(12):2313-8. PubMed ID: 16269974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
